Automated Insulin Delivery

Analysis of the MarketScan database showed a strong association between flash continuous glucose monitoring (CGM) use and significant reductions in diabetes-related events and hospitalizations in a cohort of 10,282 adults with type 2 diabetes.

Although the authors say their findings shed light on possible disruptions to insulin supply during COVID-19, they note they could not adjust for those with diabetes who died.

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association (ADA), talks about the "old-fashioned" finger stick requirement for continuous glucose monitoring.